Autolus Therapeutics (AUTL) Depreciation and Depletion (2018 - 2025)

Autolus Therapeutics (AUTL) has reported Depreciation and Depletion for 8 consecutive years, with $2.1 million the latest figure, recorded in Q4 2025.

• Quarterly Depreciation and Depletion rose 5.0% year-over-year to $2.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.3 million (up 9.21% YoY) and the FY2025 annual result came in at $8.3 million, up 9.21% from the prior year.
• Depreciation and Depletion was little changed at $2.1 million in Q4 2025 per AUTL's latest filing, from $2.1 million in the prior quarter.
• Over the last five years, Depreciation and Depletion for AUTL reached as high as $2.4 million in Q3 2021 and fell as low as $1.4 million in Q3 2023.
• A 5-year average of $1.9 million and a median of $1.9 million in 2022 frame the typical range for Depreciation and Depletion.
• Annual changes were most pronounced in 2021 — Depreciation and Depletion jumped 83.33% — and 2022, when it declined 25.0%.
• Year by year, Depreciation and Depletion stood at $2.1 million in 2021, then retreated by 23.81% to $1.6 million in 2022, then advanced by 12.5% to $1.8 million in 2023, then climbed by 11.11% to $2.0 million in 2024, then increased by 5.0% to $2.1 million in 2025.
• According to Business Quant data, Depreciation and Depletion over the past three periods registered $2.1 million, $2.1 million, and $2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.